Latest BPH Stories
QUEBEC CITY, Aug. 17 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.
All amounts are in U.S. dollars QUEBEC CITY, Aug. 11 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.
SOUTHAMPTON, England, June 29 /PRNewswire/ -- Vantia Therapeutics, an emerging pharmaceutical company developing novel, small molecule drugs targeting large, underserved medical markets, announces positive results from a Phase IIa clinical trial of its lead development compound VA106483 for nocturia.
QUEBEC CITY, June 10 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.
Initial results from preclinical and Phase 1 safety studies, and plans for Phase 2 studies for menopausal symptoms and benign prostatic hyperplasia (BPH) are to be presented CINCINNATI, May 14 /PRNewswire/ -- Ausio Pharmaceuticals, LLC, a biotechnology development company focused on medicines for an aging global population, will lead off the Bio(R) Business Forum in a presentation on May 19, 2009 at 9:00 AM in Atlanta, Georgia.
- Significant peak urine flow (Qmax) improvements within 2-6 hours of the first dose, according to published data - CORONA, Calif., May 8 /PRNewswire-FirstCall/ -- RAPAFLO(TM) (silodosin), a new, uniquely selective alpha blocker for the treatment of the signs and symptoms of BPH, produces rapid improvements of both irritative and obstructive urinary symptoms that were sustained for 12 weeks, according to data published in the June issue of The Journal of Urology.
All amounts are in U.S. dollars QUEBEC CITY, May 6 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.
- Uniquely Selective Agent Offers Significant Improvement - CHICAGO, April 28 /PRNewswire-FirstCall/ -- Data to be presented at the American Urological Association's (AUA) Annual Conference show that RAPAFLO(TM) (silodosin) produces rapid and sustained improvements of both irritative and obstructive urinary symptoms associated with BPH, with statistically significant symptom relief within three to four days of starting treatment.
-- Data Presented at American Urological Association Annual Meeting -- SEATTLE and CHICAGO, April 28 /PRNewswire-FirstCall/ -- Researchers from Dendreon Corporation (Nasdaq: DNDN) today presented preclinical data demonstrating the potential of D-3263, Dendreon's orally bioavailable small molecule, which targets TRPM8 (a transmembrane cation channel protein), to treat benign prostatic hyperplasia (BPH).
DENVER, April 27 /PRNewswire-USNewswire/ -- Phase II data presented at the annual meeting of the American Urology Association (AUA) indicate that men suffering from an enlarged prostate may benefit from BOTOX(R) injections.
- The act of sweetening by admixture of some saccharine substance.